MFG
VRTX icon

Menard Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Menard Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,951
Closed -$869K – 99
2025
Q2 		$869K Buy
1,951
+169
+9% +$77.9K 0.52% 40
2025
Q1 		$802K Buy
1,782
+152
+9% +$70.8K 0.53% 42
2024
Q4 		$656K Buy
1,630
+187
+13% +$86.7K 0.39% 54
2024
Q3 		$671K Buy
+1,443
New +$693K 0.44% 54

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Menard Financial Group's VRTX Position: Q3 2025 in Review

Menard Financial Group sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 1,951 shares — an estimated $869K sold.

Menard Financial Group first reported a position in VRTX in Q3 2024 and held it in 4 quarters. The position peaked at $869K in Q2 2025. 1,520 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Menard Financial Group reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Menard Financial Group sold 1,951 Vertex Pharmaceuticals shares in Q3 2025, an estimated $869K.
  • Menard Financial Group first reported a position in Vertex Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Menard Financial Group's Vertex Pharmaceuticals position peaked at $869K in Q2 2025.
  • 1,520 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Menard Financial Group's 13F filing for Q3 2025, filed 14 Nov 2025.